Candesartan to prevent heart failure in certain gene carriers
Treatments studied
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests whether candesartan (a blood-pressure medicine) can delay or prevent heart muscle weakening in people who carry a disease-causing dilated cardiomyopathy gene variant but still have fairly strong heart pumping. Participants are randomly assigned to candesartan or a placebo to see which one keeps the heart healthier over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–64 years old and can legally consent
- You carry a pathogenic or likely pathogenic dilated cardiomyopathy gene variant
- Your heart pumping strength is preserved (left ventricle ejection fraction 50% or higher) on a heart MRI
- Your kidney blood tests are acceptable (creatinine ≤ 1.3, potassium ≤ 5.3, and eGFR ≥ 60)
- Your blood pressure is not too low (systolic must be 100 or higher) and not uncontrolled high
- You are able and willing to get MRI scans and take the study medicine/placebo safely
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication that may help people with a specific type of heart disease (ATTR amyloidosis) and heart failure with reduced pumping function. The treatment could slow disease progression and improve symptoms.
This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.
This study checks the long-term safety and effectiveness of the drug danicamtiv in people with a genetic form of dilated cardiomyopathy, a condition where the heart muscle becomes weak and enlarged. If you've already completed the earlier DAN-301 study, this trial continues to monitor you while you keep taking the medication.
This study tests whether a personalized treatment approach can improve heart function in people with dilated cardiomyopathy (a condition where the heart becomes enlarged and weak). It focuses on patients who still have low heart function despite standard medications.
This study tests a heart medication (sacubitril/valsartan) in young cancer survivors whose hearts were weakened by anthracycline chemotherapy but are not yet having heart failure symptoms. It aims to see if the drug can improve heart function and prevent future problems.
This trial tests a new medicine called CDR132L to see if it improves heart structure and function in people with heart failure who have a thickened heart muscle and reduced pumping ability. Participants will be randomly assigned to receive either the study drug or a placebo.
Hear when a new Cardiomyopathy, Dilated trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.